Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Grant | Alive

Total Raised


Last Raised

$330K | 1 yr ago

About Vivasc Therapeutics

Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. The company utilizes Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner.

Vivasc Therapeutics Headquarter Location

Pittsburgh, Pennsylvania,

United States

Latest Vivasc Therapeutics News

Ventricular Tachycardia Pipeline Monitor, 2020 Featuring Armgo Pharma, Elex Biotech, Espero BioPharma, Gilead Sciences, InCarda Therapeutics, Milestone Pharma, and Vivasc Therapeutics -

Aug 4, 2020

PIPELINE HIGHLIGHTS Ventricular Tachycardia is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline's potential. Development of Ventricular Tachycardia medicines is identified as integral to the strategy of the majority of companies operating in the industry. Global Ventricular Tachycardia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Ventricular Tachycardia. Good progress is anticipated during 2020 and 2021 with Ventricular Tachycardia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Ventricular Tachycardia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies. DRUG DEVELOPMENT PIPELINE OVERVIEW The Ventricular Tachycardia pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook. This Ventricular Tachycardia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression. The competitive intelligence report on Ventricular Tachycardia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Ventricular Tachycardia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report. DRUG PROFILES Ventricular Tachycardia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided: Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. Phase of development New molecular entity details Reasons to Buy The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment. This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data Buyers can identify most promising drug candidates for treatment of Ventricular Tachycardia It allows users to strengthen their pipeline through acquisitions, licensing and collaborations Users can estimate possible delays in the delivery of pipeline or launch of new products Stay ahead of competition through understanding their pipeline progression, strategies and outlook The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches. Optimize your licensing and technology transfer strategies through identification of prospect partners For more information about this report visit Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vivasc Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vivasc Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.



5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.